Overview of the impact of conventional systemic therapies on breast cancer.
Affiliation
CRUK Department of Medical Oncology, University of Manchester, Christie Hospital, 550 Wilmslow Road, Manchester M20 4BX, UK. Anthony.Howell@christie-tr.nwest.nhs.ukIssue Date
2005-07
Metadata
Show full item recordAbstract
Survival in women with breast cancer is improving in the western world, in part related to improved surgery, radiotherapy and adjuvant systemic therapy. Aromatase inhibitors are superior to tamoxifen in this clinical situation and several studies indicate that taxane-based chemotherapy is superior to non-taxane-based regimens. Herceptin is active alone in HER-2/neu +ve advanced breast cancer and four clinical trials are testing this agent in the adjuvant situation. It seems likely that herceptin will add to conventional therapies and thus will be the paradigm for the introduction of other biological therapies to improve cure rates.Citation
Overview of the impact of conventional systemic therapies on breast cancer. 2005, 12 Suppl 1:S9-S16 Endocr. Relat. CancerJournal
Endocrine-Related CancerDOI
10.1677/erc.1.01003PubMed ID
16113103Type
ArticleLanguage
enISSN
1351-0088ae974a485f413a2113503eed53cd6c53
10.1677/erc.1.01003
Scopus Count
Collections
Related articles
- Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
- Authors: Emens LA
- Issue date: 2005 May-Jun
- Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
- Authors: Colozza M, de Azambuja E, Personeni N, Lebrun F, Piccart MJ, Cardoso F
- Issue date: 2007 Mar
- Systemic adjuvant therapies and radiotherapy to the conserved breast: strategies revisited.
- Authors: Bartelink H
- Issue date: 2007 Dec
- [Herceptin therapy in breast cancer: new indication?].
- Authors: Lebeau A
- Issue date: 2006
- [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].
- Authors: Láng I, Hitre E
- Issue date: 2006